Trial Profile
Expanded Access to NanoPac
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Actinic keratosis; Cervical intraepithelial neoplasia; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic disorders; Plaque psoriasis; Prostate cancer; Skin cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Nanology
- 09 May 2023 Results (N=6)evaluating the immediate response and durability of response following EUS FNI of BD IPMN, presented at the Digestive Disease Week 2023
- 04 Dec 2018 New trial record